Aprea Therapeutics (NASDAQ:APRE) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. Separately, Wedbush reiterated an outperform rating and set a $11.00 price target on shares of Aprea Therapeutics in […]
More Stories
Asking Rents Decline in November: Zillow
By Naveen Athrappully Home rents across the United States edged down in November, in line with a slowdown usually seen...
US Department of State Issues Travel Advisory Against 2 Middle Eastern Countries
By Naveen Athrappully The U.S. Department of State renewed its travel advisory for two Middle Eastern nations—Yemen and Jordan—last week...
Paramount Updates Warner Bros. Offer, Affirms Ellison Family Backing
By Andrew Moran Paramount Skydance amended its offer to buy Warner Bros. Discovery on Dec. 22, guaranteeing backing from Oracle...
Japan to Resume Operations at World’s Largest Nuclear Plant 15 Years After Fukushima Disaster
By Rachel Roberts Japan is set to resume operations at the world’s largest nuclear power plant, marking a key development...
Who is Yeonjun? Band, Age, Albums, and Updates
One of the eldest and all-around band members of TXT (TOMORROW X TOGETHER), Yeonjun. He is the only member born...
Skip the Spa: Achieving Relaxation with a Backyard Sauna Kit
A luxurious spa visit is no longer necessary for those seeking a tranquil and calming environment for relaxation. Many homeowners...